Jürgen Brockmöller mainly focuses on Pharmacology, Pharmacokinetics, Internal medicine, Genotype and Genetics. His research in Pharmacology intersects with topics in CYP2D6, Pharmacogenetics and NADH oxidase. The various areas that he examines in his Pharmacokinetics study include CYP2C9, Hypericin, Adverse effect and Hypericum perforatum.
His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology, Oncology and Drug. His studies deal with areas such as Gastroenterology, Lung cancer, Therapeutic drug monitoring and Immunology as well as Genotype. His Allele study introduces a deeper knowledge of Gene.
Jürgen Brockmöller focuses on Pharmacology, Pharmacokinetics, Internal medicine, Pharmacogenetics and Genotype. His Pharmacology research includes themes of CYP2D6, CYP2C9 and Metabolite. In his research, Messenger RNA is intimately related to CYP3A4, which falls under the overarching field of Pharmacokinetics.
While the research belongs to areas of Internal medicine, Jürgen Brockmöller spends his time largely on the problem of Endocrinology, intersecting his research to questions surrounding In vivo and Biochemistry. His Genotype research integrates issues from Lung cancer, Allele and Genetic predisposition. In his study, Gene expression is inextricably linked to Molecular biology, which falls within the broad field of Allele.
Jürgen Brockmöller spends much of his time researching Pharmacology, Pharmacokinetics, Organic cation transport proteins, Internal medicine and Pharmacogenetics. He interconnects CYP2D6, Hydromorphone, CYP2C19 and Oxymorphone in the investigation of issues within Pharmacology. Jürgen Brockmöller has included themes like Molecular biology and Endogeny in his Organic cation transport proteins study.
The Internal medicine study combines topics in areas such as Endocrinology, Genome-wide association study, Allele and Oncology. His study on Pharmacogenetics is covered under Genotype. His Genotype research is multidisciplinary, relying on both Analgesic and Confidence interval.
Pharmacokinetics, Internal medicine, Pharmacology, Organic cation transport proteins and Transcranial magnetic stimulation are his primary areas of study. The concepts of his Pharmacokinetics study are interwoven with issues in Green tea extract, Green tea, Pharmacogenetics and Adverse effect. Jürgen Brockmöller has researched Pharmacogenetics in several fields, including Analgesic, Tramadol, Confidence interval, Metabolite and CYP2D6.
CYP2D6 is a subfield of Genotype that Jürgen Brockmöller explores. His Internal medicine study combines topics in areas such as Endocrinology and Allele. His Pharmacology research is multidisciplinary, incorporating elements of CYP2C19 and Malaria.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
S. Hoffmeyer;O. Burk;O. von Richter;H. P. Arnold.
Proceedings of the National Academy of Sciences of the United States of America (2000)
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
C Sachse;J Brockmöller;S Bauer;I Roots.
American Journal of Human Genetics (1997)
Metabolic Gene Polymorphism Frequencies in Control Populations
S. Garte;L. Gaspari;A.K. Alexandrie;C. Ambrosone.
Cancer Epidemiology, Biomarkers & Prevention (2001)
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Kirchheiner J;Nickchen K;Bauer M;Wong Ml.
Molecular Psychiatry (2004)
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
Christoph Sachse;Jürgen Brockmöller;Steffen Bauer;Ivar Roots.
British Journal of Clinical Pharmacology (1999)
The genetic determinants of the CYP3A5 polymorphism
Elisabeth Hustert;Michael Haberl;Oliver Burk;Renzo Wolbold.
Clinical consequences of cytochrome P450 2C9 polymorphisms.
Julia Kirchheiner;Jürgen Brockmöller.
Clinical Pharmacology & Therapeutics (2005)
Nomenclature for human CYP2D6 alleles.
A K Daly;J Brockmoller;F Broly;M Eichelbaum.
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
J Kirchheiner;K Brosen;Marja-Liisa Dahl;LF Gram.
Acta Psychiatrica Scandinavica (2001)
Combined Analysis of Inherited Polymorphisms in Arylamine N-Acetyltransferase 2, Glutathione S-Transferases M1 and T1, Microsomal Epoxide Hydrolase, and Cytochrome P450 Enzymes as Modulators of Bladder Cancer Risk
Jürgen Brockmöller;Ingolf Cascorbi;Reinhold Kerb;Ivar Roots.
Cancer Research (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: